Advertisement

Related Videos

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Advertisement

Advertisement




Jan
21
Today In Oncology
IMPT vs IMRT in Oropharyngeal Cancer
Investigational Vaccine Intercepts Cancer Cells in Lynch Syndrome Carriers
Regulatory Agencies Establish Principles of Good AI Use in Drug Development
Genetic Predisposition to Higher Body Mass Index Linked to Mortality After Breast Cancer
Axillary Recurrence With or Without ALND in Patients With Residual Micrometastases After Neoadjuvant Chemotherapy for Breast Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo